CDC42 and cancer: Host signaling pathways have been acknowledged as therapeutic targets in cancer and viral infections, with tyrosine kinases (TKs) being profoundly explored, and many TK inhibitors (TKIs) have been approved by the FDA for cancer treatment [32,33,34].